2026-05-20T03:51:01Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/192912025-05-08T15:11:37Zcom_20.500.12105_2052com_20.500.12105_2051col_20.500.12105_19612

00925njm 22002777a 4500 dc Ørnbjerg, Lykke Midtbøll author Brahe, Cecilie Heegaard author Linde, Louise author Jacobsson, Lennart author Nissen, Michael J author Kristianslund, Eirik Klami author Santos, Maria José author Nordström, Dan author Rotar, Ziga author Gudbjornsson, Bjorn author Onen, Fatos author Codreanu, Catalin author Lindström, Ulf author Möller, Burkhard author Kvien, Tore K author Barcelos, Anabela author Eklund, Kari K author Tomšič, Matija author Love, Thorvardur Jon author Can, Gercek author Ionescu, Ruxandra author Loft, Anne Gitte author Mann, Herman author Pavelka, Karel author van de Sande, Marleen author van der Horst-Bruinsma, I E author Pombo Suarez, Manuel author Sanchez-Piedra, Carlos author Macfarlane, Gary J author Iannone, Florenzo author Michelsen, Brigitte author Hyldstrup, Lise Hejl author Krogh, Niels Steen author Østergaard, Mikkel author Hetland, Merete Lund author 2024-04-04 Objective: To investigate real-world retention and remission rates in PsA patients initiating a 2nd or 3rd TNFi and the association with reason for discontinuation from the previous TNFi-treatment. Methods: Prospectively collected routine care data from 12 European registries were pooled. Retention rates (Kaplan-Meier estimation) and crude/LUNDEX-adjusted rates of Disease Activity Score 28 and Disease Activity index for PSoriatic Arthritis (DAS28 and DAPSA28) remission were calculated and compared with adjusted Cox regression analyses and Chi-squared test, respectively). Results: We included 5233 (2nd TNFi) and 1906 (3rd TNFi) patients. Twelve-month retention rates for the 2nd and 3rd TNFi were 68% (95%CI: 67-70%) and 66% (64-68%), respectively. Patients who stopped the previous TNFi due to AE/LOE had 12-month retention rates of 66%/65% (2nd TNFi), and 65%/63% (3rd TNFi), respectively. Patients who stopped the previous TNFi due to LOE after less vs more than 24 weeks had 12-month retention rates of 54%/69% (2nd TNFi), and 58%/65% (3rd TNFi). Six-month crude/LUNDEX-adjusted DAS28 remission rates were 48%/35% and 38%/27%, and DAPSA28 remission rates were 19%/14% and 14%/10%, for the 2nd and 3rd TNFi. Conclusion: Two-thirds of patients remained on TNFi at 12months for both the 2nd and 3rd TNFi, while one-third and one-quarter of patients were in DAS28 remission after 6months on the 2nd and 3rd TNFi. While drug effectiveness was similar in patients who stopped the previous TNFi due to AE compared to overall LOE, drug effectiveness was better in patients who had stopped the previous TNF due to secondary LOE compared to primary LOE. Joint Bone Spine. 2024 Apr 4;91(4):105729. 10.1016/j.jbspin.2024.105729 1778-7254 Joint bone spine 38582359 http://hdl.handle.net/20.500.12105/19291 Psoriatic arthritis TNF-inhibitors Epidemiology Treatment withdrawal Drug effectiveness of 2nd and 3rd TNF inhibitors in psoriatic arthritis - relationship with the reason for withdrawal from the previous treatment